SPN-810M
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Impulsive Aggression Comorbid With ADHD
Conditions
Impulsive Aggression Comorbid With ADHD
Trial Timeline
Nov 1, 2013 → Dec 1, 2013
NCT ID
NCT02023606About SPN-810M
SPN-810M is a phase 1 stage product being developed by Supernus Pharmaceuticals for Impulsive Aggression Comorbid With ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT02023606. Target conditions include Impulsive Aggression Comorbid With ADHD.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02023606 | Phase 1 | Completed |
Competing Products
2 competing products in Impulsive Aggression Comorbid With ADHD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Molindone | Supernus Pharmaceuticals | Phase 2 | 47 |
| SPN-810 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |